Celcuity Inc.

About Celcuity Inc.

Celcuity is a clinical-stage biotechnology company focused on unraveling complex oncogenic activity and harnessing insights to develop new targeted therapies for cancer patients. Their mission is to discover previously undetectable cancer drivers and create drugs to treat them, providing options and delivering hope.

Products & Services

Gedatolisib:A pan-PI3K, mTORC1/2 inhibitor that comprehensively blocks the PI3K/AKT/mTOR (PAM) pathway, currently a lead candidate in clinical trials for breast and prostate cancer.

Cellular Analysis Platform:A third-generation platform that unravels complex oncogenic activity undetectable by molecular tests, used to identify new applications for targeted therapies.

Specialties

Cancer Research Targeted Therapies Oncogenic Pathway Analysis PI3K/AKT/mTOR (PAM) Pathway Inhibition Clinical Trials for Breast and Prostate Cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 500000000 MR: - FA: 500 million USD FAN: 500000000	D: 2025-09-09 FD: 2025-09-09	2 investors
2	RT: Convertible Debt T: - FT: Convertible Debt	A: 175000000 MR: - FA: $175,000,000 FAN: 175000000	D: 2025-07-30 FD: 2025-07-30	-
3	RT: Convertible Senior Notes and Common Stock Offering T: - FT: Convertible Senior Notes and Common Stock Offering	A: 225000000 MR: - FA: $150,000,000 for Convertible Notes and $75,000,000 for Common Stock FAN: 225000000	D: 2025-07-28 FD: 2025-07-28	4 investors
4	RT: Underwritten Common Stock Offering T: - FT: Underwritten Common Stock Offering	A: 60000000 MR: - FA: $60.0 million FAN: 60000000	D: 2024-05-30 FD: 2024-05-30	6 investors
5	RT: Private Placement T: - FT: Private Placement	A: 50000000 MR: - FA: 50 million FAN: 50000000	D: 2023-10-18 FD: 2023-10-18	1 investors

Debt Latest

2025-09-09

$500.0M

2 investors (Pro only)

Convertible Debt 2025-07-30

$175.0M

Convertible Senior Notes and Common Stock Offering 2025-07-28

$225.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Manfred Auer

Research Professor of Chemical and Translational Biology of the Scottish Universities Life Sciences Alliance at the University of Edinburgh

A

Adam Brufsky

Professor of Medicine

E

Edward Greeno

Medical Director of the Hematology/Oncology Clinic and Associate Professor at the University of Minnesota Medical School

S

Sara Hurvitz

Director, Breast Cancer Clinical Research Programs and Assistant Professor of Medicine, Division of Hematology/Oncology

B

Benita Katzenellenbogen

Swanlund Professor of Molecular and Integrative Physiology and Swanlund Professor of Cell and Developmental Biology at the University of Illinois School of Molecular and Cellular Biology

J

John Katzenellenbogen

Research Professor of Chemistry

View 31 more team members with Pro

Unlock Full Team Directory

Recent News

Celcuity Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised